MoonLake - MLTX Total Company Value-to-Revenue Ratio

MoonLake (MLTX) - corporate logo

The change in the enterprise value-to-revenue ratio clearly demonstrates the market valuation of MoonLake Immunotherapeutics (MLTX), where 0.00 determines the current status of the parameter. The company's revenues are based on the market launch of innovative sonelokimab nanobodies. High loyalty among the staff of immunologists supports the pace of development, which is critical for successfully passing clinical trials and subsequent sales of the drug to patients with severe inflammation.

MLTX MoonLake Immunotherapeutics: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

MLTX (moonlaketx.com): analytical breakdowns and indicator data

- cash and cash flow indicators:
Initial company analysis:MLTX, moonlaketx.com
Manufactured product of MoonLake Immunotherapeutics

The investment attractiveness of MoonLake Immunotherapeutics (MLTX) is based on the potential for premium pricing of sonelokimab, which creates a foundation for exponential growth in future cash flows. This metric compares the enterprise value (EV), including debt, to current sales volume, reflecting the market's revaluation of every dollar of revenue. By analyzing the change in the company's EV-to-revenue ratio, an investor can assess the asset's fundamental margin of safety prior to the drug's commercialization.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue Crinetics Pharmaceuticals CRNX|Enterprise Value-to-Revenue Ratio NewAmsterdam Pharma N.V. NAMS|Total Company Value-to-Revenue Ratio Soleno Therapeutics Inc (SLNO)|FOLD - Enterprise Value-to-Revenue Ratio|ETNB: Enterprise Value-to-Revenue Ratio|AGIO: EV/Sales Multiple|Structure Therapeutics Inc. - Business Value to Revenue|MDXG (MiMedx Corp) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Rezolute Inc RZLT|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)